Skip to content

Breast Cancer Health Center

Font Size

Stage I, II, IIIA, and Operable IIIC Breast Cancer

    Table 6. Standard Adjuvant Chemotherapy Regimens for Stage I, II, IIIA, and Operable IIICHER2/neuNon-Overexpressing Breast Cancer continued...

    In the combined analysis of the NSABP-B-31 (NCT00004067) and Intergroup NCCTG-N9831 trials, trastuzumab was given weekly, concurrently, or immediately after the paclitaxel component of the AC with paclitaxel regimen.[202][Level of evidence: 1iiA] The results were confirmed in a joint analysis of the two studies, with a combined enrollment of 3,676 patients, that demonstrated a highly significant improvement in DFS (HR, 0.48; P < .001; 3-year DFS = 87% vs. 75%), as well as a significant improvement in OS (HR, 0.67; P = .015; 3-year OS = 94.3% vs. 91.7%; 4-year OS = 91.4% vs. 86.6%).[203] Patients treated with trastuzumab experienced a longer DFS with a 52% lower risk of a DFS event (HR, 0.48; 95% CI, 0.39–0.59; P < .001), corresponding to an absolute difference in DFS of 11.8% at 3 years and 18% at 4 years. The risk of distant recurrence was 53% lower (HR, 0.47; 95%CI, 0.37–0.61; P < .001) in patients treated with trastuzumab, and the risk of death was 33% lower (HR, 0.67; 95%CI, 0.48–0.93; P = .015) in these patients.

    In the BCIRG-006 (NCT00021255) trial, 3,222 women with early stage HER2-overexpressing breast cancer were randomly assigned to receive AC followed by docetaxel (AC-T) versus AC followed by docetaxel plus trastuzumab (AC-T plus trastuzumab) versus docetaxel, carboplatin, plus trastuzumab (TCH, a nonanthracycline-containing regimen).[204][Level of Evidence: 1iiA] A significant benefit with respect to DFS and OS was seen in both groups treated with trastuzumab-containing regimens compared with the control group that did not receive trastuzumab. The control group had a 5-year DFS rate of 75% and an OS rate of 87%. For patients receiving AC-T plus trastuzumab, the 5-year DFS rate was 84% (HR for the comparison with AC-T = 0.64; P < .001), and the OS rate was 92% (HR, 0.63; P < .001). For patients receiving TCH, the 5-year DFS rate was 81% (HR, 0.75; P = .04), and the OS rate was 91% (HR, 0.77; P = .04).

    1|2|3|4|5|6|7|8|9|10|11|12|13|14|15|16|17|18|19|20|21|22|23|24|25|26|27|28|29|30|31|32|33|34|35|36|37|38|39

    Today on WebMD

    Breast Cancer Overview
    From self-exams and biopsies to reconstruction, we’ve got you covered.
    Dealing with breast cancer
    Get answers to your questions.
     
    woman having mammogram
    Experts don’t agree on all fronts, but you can be your own advocate.
    woman undergoing breast cancer test
    Many women worry. But the truth? Most abnormalities aren’t breast cancer.
     
    Breast Cancer Treatments Improving
    VIDEO
    Resolved To Quit Smoking
    SLIDESHOW
     
    Woman getting mammogram
    Article
    Screening Tests for Women
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    serious woman
    Article
     
    what is your cancer risk
    HEALTH CHECK
    10 Ways to Revitalize Slideshow
    SLIDESHOW
     

    WebMD Special Sections